Company: BIVIW
Filing Date: 2025-07-22
Form Type: S-1/A
Source: 0001520138-25-000216
Chunk: 60

Company: BIOVIE INC.
Filing Date: 2025-07-22
Form: S-1/A
Chunk 60
---
pects.

We may be subject to claims challenging the inventorship of our patents and other intellectual property.

We or our licensors may be subject to claims that
former employees, collaborators or other third parties have an interest (including co-ownership or ownership) in our owned or in-licensed
patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors or collaborators
may have inventorship disputes arising from conflicting obligations of employees, consultants or others who are involved in developing
our drug candidates. While it is our policy to require our employees and contractors who may be involved in the development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with
each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing
or may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors’
or collaborators’ ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors
or collaborators fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights, such as exclusive ownership of, or right to use, intellectual property that is important to our drug candidates. Even if we are
successful in defending against such claims, these claims may create considerable distraction to management and other employees of the
company. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

Intellectual property rights do not necessarily address all potential threats.

The degree of future protection, if any, afforded
by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect
our business or permit us to maintain our competitive advantage. For example:

| · | others may be able to make products that are similar to any drug candidates we may develop or utilize              
 similar technology but that are not covered by the claims of the patents that we license or may own in the future; |

| · | we, or our current or future licensors or collaborators, might not have been the first to make the inventions 
 covered by the issued patent or pending patent application that we license or may own in the future;          |

| · | we, or our current or future licensors or collaborators might not have been the first to file patent applications 
 covering certain of our or their invention